CN1785253A - Micro-balls of compounding red-rooted salvia injection, and its prepn. method - Google Patents
Micro-balls of compounding red-rooted salvia injection, and its prepn. method Download PDFInfo
- Publication number
- CN1785253A CN1785253A CN 200410093890 CN200410093890A CN1785253A CN 1785253 A CN1785253 A CN 1785253A CN 200410093890 CN200410093890 CN 200410093890 CN 200410093890 A CN200410093890 A CN 200410093890A CN 1785253 A CN1785253 A CN 1785253A
- Authority
- CN
- China
- Prior art keywords
- salviae miltiorrhizae
- acid
- microsphere
- radix salviae
- borneolum syntheticum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 240000007164 Salvia officinalis Species 0.000 title claims abstract description 16
- 238000002347 injection Methods 0.000 title abstract description 7
- 239000007924 injection Substances 0.000 title abstract description 7
- 239000011806 microball Substances 0.000 title abstract description 6
- 235000017276 Salvia Nutrition 0.000 title description 11
- 238000013329 compounding Methods 0.000 title description 5
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 40
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 40
- 239000000284 extract Substances 0.000 claims abstract description 32
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 24
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 235000005412 red sage Nutrition 0.000 claims abstract description 5
- 239000004005 microsphere Substances 0.000 claims description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 35
- 238000002360 preparation method Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 244000131316 Panax pseudoginseng Species 0.000 claims description 12
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 12
- 229920000954 Polyglycolide Polymers 0.000 claims description 11
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 11
- 239000004633 polyglycolic acid Substances 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 238000001694 spray drying Methods 0.000 claims description 10
- 208000035126 Facies Diseases 0.000 claims description 9
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- 239000004626 polylactic acid Substances 0.000 claims description 9
- -1 polypropylene Polymers 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 239000012362 glacial acetic acid Substances 0.000 claims description 6
- 239000012875 nonionic emulsifier Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 230000001804 emulsifying effect Effects 0.000 claims description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 5
- 239000012071 phase Substances 0.000 claims description 5
- 210000005239 tubule Anatomy 0.000 claims description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
- 239000006185 dispersion Substances 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 3
- 229920000193 polymethacrylate Polymers 0.000 claims description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 3
- 238000000935 solvent evaporation Methods 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 2
- 241001597008 Nomeidae Species 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 150000002148 esters Chemical group 0.000 claims description 2
- 229960004275 glycolic acid Drugs 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000151 polyglycol Polymers 0.000 claims description 2
- 239000010695 polyglycol Substances 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229920000642 polymer Polymers 0.000 claims 4
- 238000002156 mixing Methods 0.000 claims 2
- 238000004090 dissolution Methods 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 84
- 238000000605 extraction Methods 0.000 description 28
- 239000007788 liquid Substances 0.000 description 28
- 239000000706 filtrate Substances 0.000 description 20
- 239000012567 medical material Substances 0.000 description 20
- 238000001914 filtration Methods 0.000 description 14
- 239000012141 concentrate Substances 0.000 description 12
- 230000006837 decompression Effects 0.000 description 8
- 238000013019 agitation Methods 0.000 description 7
- 238000010438 heat treatment Methods 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 238000010298 pulverizing process Methods 0.000 description 7
- 238000004064 recycling Methods 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 244000132619 red sage Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002481 ethanol extraction Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 238000012856 packing Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 102000011759 adducin Human genes 0.000 description 3
- 108010076723 adducin Proteins 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical group OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- ZRJBHWIHUMBLCN-SEQYCRGISA-N Huperzine A Natural products N1C(=O)C=CC2=C1C[C@H]1/C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-SEQYCRGISA-N 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- ZRJBHWIHUMBLCN-UHFFFAOYSA-N Shuangyiping Natural products N1C(=O)C=CC2=C1CC1C(=CC)C2(N)CC(C)=C1 ZRJBHWIHUMBLCN-UHFFFAOYSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000008899 fufang danshen Substances 0.000 description 2
- ZRJBHWIHUMBLCN-YQEJDHNASA-N huperzine A Chemical compound N1C(=O)C=CC2=C1C[C@H]1\C(=C/C)[C@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-YQEJDHNASA-N 0.000 description 2
- 239000006101 laboratory sample Substances 0.000 description 2
- ZRJBHWIHUMBLCN-BMIGLBTASA-N rac-huperzine A Natural products N1C(=O)C=CC2=C1C[C@@H]1C(=CC)[C@@]2(N)CC(C)=C1 ZRJBHWIHUMBLCN-BMIGLBTASA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011805 ball Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013563 matrix tablet Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000005325 percolation Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007560 sedimentation technique Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229930189533 tanshinol Natural products 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A microball used for compound red sage root injection contains the active components (the extracts of red sage root and notoginseng, and borneol), and biodegradable medicinal high-molecular auxiliary. Its preparing process is also disclosed.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of compound slow-releasing red-rooted salvia injection microsphere and preparation method thereof.
Background technology
The compound Salviae Miltiorrhizae prescription has blood circulation promoting and blood stasis dispelling, the effect of regulating QI to relieve pain.Be used for the treatment of in the heart and feel oppressed, angina pectoris, it mainly consists of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum.Through clinical practice for many years, people recognize gradually that except that above-mentioned effect compound Salviae Miltiorrhizae also has the blood fat of accent, atherosclerosis (AS); Effects such as treatment cerebral infarction.Since coming out from the seventies in last century, it has been subjected to the favorable comment of extensive patients.
The oral formulations of compound Salviae Miltiorrhizae is a tablet all the time, continuous development along with pharmaceutics, the research of relevant compound red sage root preparation is also more and more, as compound Salviae Miltiorrhizae granule, compound Salviae Miltiorrhizae oral liquid, compound Salviae Miltiorrhizae soft gelatin capsule, FUFANG DANSHEN JIAONANG, compound Salviae Miltiorrhizae aerosol and FUFANG DANSHEN DIWAN etc.But owing to the intravital half-life of water-soluble active ingredient in the Radix Salviae Miltiorrhizae is shorter, make common oral formulations be faced with a series of problem, frequent as the clinical administration number of times, use inconvenience, patient's compliance (compliance) difference etc.
Inventor's process years of researches find that Radix Salviae Miltiorrhizae, pseudo-ginseng are extracted the back makes microsphere with suitable adjuvant, can reach non-lentamente constant release, reduce and take number of times, improve the purpose of patient's compliance.
Summary of the invention
The object of the invention has been to provide a kind of brand-new slow release, the micro-balls of compounding red-rooted salvia injection of high bioavailability.
Another object of the present invention is to provide the preparation method of this micro-balls of compounding red-rooted salvia injection.
Compound Salviae Miltiorrhizae prescription of the present invention is (in a weight percentage):
Radix Salviae Miltiorrhizae 48%～97%
Radix Notoginseng 2%～50%
Borneolum Syntheticum 0.2%～3%
The optimizing prescriptions proportioning is (in a weight percentage):
Radix Salviae Miltiorrhizae 63.0%～94%
Radix Notoginseng 4.0%～35.0%
Borneolum Syntheticum 0.5%～2.0%
Further the optimizing prescriptions proportioning is (in a weight percentage):
Radix Salviae Miltiorrhizae 75.2%～90%
Radix Notoginseng 9%～23.5%
Borneolum Syntheticum 0.5%～1.3%
The best prescription proportioning is (in a weight percentage):
Radix Salviae Miltiorrhizae 82.87%
Radix Notoginseng 16.21%
Borneolum Syntheticum 0.92%
Said medicine prescription proportioning is the weight proportion of institute's uses crude drug, if it is need be to described Radix Salviae Miltiorrhizae, Radix Notoginseng further independent or mixed extraction is processed into extract and suitable adjuvant is made gel matrix tablet to be made into preparation.Extracting method wherein is selected from (but being not limited to this): decoction and alcohol sedimentation technique, percolation, column chromatography method etc.
For the ease of understanding, the existing extracting method in present technique field is described below for example, but is not limited to this.
The Radix Salviae Miltiorrhizae water extraction: get red rooted salvia, 20 mesh sieves are pulverized, extracting in water 2 times, the water logging bubble that adds for the first time 9～10 times of amounts, heating extraction 1.5 hours adds 5～7 times of water gagings, heating extraction 1 hour for the second time, merge extractive liquid,, suitably concentrate, add 95% ethanol, make to contain alcohol amount arrival 50%～70%, concentrate and reclaim ethanol, get Radix Salviae Miltiorrhizae extract.
The tanshinol extraction method: get red rooted salvia, 20 mesh sieves are pulverized, and 7～9 times of amount 70% alcohol heating reflux extract 2 times, each 1 hour, merge extractive liquid,, concentrate Radix Salviae Miltiorrhizae extract.
The extraction of active component of red sage root: get red rooted salvia, 20 mesh sieves are pulverized, water or ethanol extraction concentrate, and add ethanol precipitation, be dissolved in water after reclaiming ethanol, last macroporous resin chromatography separates, after water elution is removed impurity, ethanol elution to effective ingredient fully till, reclaim ethanol, get exsiccant Radix Salviae Miltiorrhizae extract.
The ethanol extraction of Radix Notoginseng: add the ethanol extraction 3 times of 10 times of amount 10%～30% concentration, reflux 8 hours, merge extractive liquid, concentrates and reclaims ethanol, Radix Notoginseng extract.
Radix Notoginseng column chromatography method: get Radix Notoginseng, suitably pulverize, add ethanol and divide 2 extractions, filter, merge filtering, decompression recycling ethanol is to a certain amount of, add suitable quantity of water, continuing to be recycled to does not have the alcohol flavor, and it is past that medicinal liquid is crossed pretreated macroporous adsorbent resin, and it is colourless to be washed to filter liquor, continue to use 50% ethanol elution, collect eluent, concentrate, get Radix Notoginseng extract.
Except that the independent extraction of above-mentioned medical material, described Radix Salviae Miltiorrhizae, all right mixed extraction of Radix Notoginseng are mainly: Radix Salviae Miltiorrhizae, the pseudo-ginseng of learning from else's experience and pulverizing, and boiling water boils to be carried, filter, merging filtrate, and filtrate is suitably concentrated; Add ethanol and carry out precipitate with ethanol in concentrated solution, leave standstill, supernatant reclaims ethanol, is condensed into extractum, gets medicinal substances extract.
Be used as medicine after described Borneolum Syntheticum is directly pulverized and get final product.
Micro-balls of compounding red-rooted salvia injection diameter of the present invention is 1～250 μ m, is made up of at 5000～1000000 daltonian biodegradable medical high-molecular additives the active component of microsphere gross weight 0.2%～50% (w/w) and the molecular weight of derivant and microsphere gross weight 50～99.8% (w/w) thereof.Wherein said biodegradable medical high-molecular additive is selected from polylactide. Acetic acid, hydroxy-, bimol. cyclic ester, polylactic acid, polyglycolic acid, poly--the 3-butyric ester, polylactic acid-polyglycolic acid, polylactic acid. and glycolic, poly-adjacent ester, polylactone, polyanhydride, poly butyric ester-hydroxyl pentanoate copolymer, polyglycolic acid, polypropylene glucosan, hydroxyacetic acid, polylactic acid-polyglycol, polyglycolic acid. wherein a kind of of Polyethylene Glycol; Preferred polylactide-co-glycolide, polylactic acid, polylactic acid. polyglycolic acid, polylactic acid. glycolic, poly butyric ester-hydroxyl pentanoate copolymer, the best is a polylactide. Acetic acid, hydroxy-, bimol. cyclic ester, molecular weight are 12000～15000 dalton; The polymerization ratio of lactide-Acetic acid, hydroxy-, bimol. cyclic ester is 40: 60-60: 40.
Microsphere of the present invention can adopt the conventional preparation method of microsphere to make, as adopting emulsifying dispersion method, spray drying method and solvent evaporation method, preferably spray drying method.When preparing microsphere of the present invention with the emulsifying dispersion method, with dichloromethane, chloroform, ethyl acetate, dioxane, ether, acetone, oxolane, glacial acetic acid and by the mixed acid that they are formed huperzine A or derivatives thereof and the dissolving of biodegradable pharmaceutic adjuvant are mixed with organic facies, wherein the bulking value percent of pharmaceutic adjuvant in organic solvent is 1～30%, the emulsifying agent that organic facies adopts is the nonionic emulsifier of HBL=4.5～6.0, and consumption is the 0.01-12% of organic facies; Prepare continuous water with polyvinyl alcohol, polyvinyl pyrrolidone, sodium polymethacrylate, sodium polyacrylate, sodium carboxymethyl cellulose solution in addition, wherein they are 0.01～10.0% in the percetage by weight of aqueous phase, the emulsifying agent of aqueous phase is the nonionic emulsifier of HLB=14.0～15.5, and consumption is 0.01～12% of a water; The volume ratio of organic facies and water is 1: 4～100; Organic facies slowly is injected in the continuous phase by tubule, fully emulsified after, the formed microsphere of sieving separating is drying to obtain.When adopting solvent evaporation method, be decentralized photo slowly be injected into by tubule in the continuous phase fully emulsified after, the decompression solvent flashing, centrifugalize obtains formed microsphere, is drying to obtain.
When adopting the attached side's Radix Salviae Miltiorrhizae of spray drying method for preparation microsphere, to be the mixed acid formed with dichloromethane, chloroform, ethyl acetate, dioxane, ether, acetone, oxolane, glacial acetic acid and by them compound Salviae Miltiorrhizae and biodegradable pharmaceutic adjuvant fully dissolve is mixed with organic solution; Filter, spray drying is made microsphere.
Compound Salviae Miltiorrhizae microsphere of the present invention be will make microsphere sterilized powder suspendible in aseptic 0.9% normal saline solvent earlier, evenly the back intramuscular injection comes administration.
In motherland's medical science to record that pill has " the ball person is slow also, releives and controls it ... " (Li Gao, 1180-1251).As seen Ancient Times in China medicine man early has recognized that and has used practice of pharmacy, reaches the purpose of steadily lasting curative effect.
Conventional dosage forms, most drug release process is all undertaken by first order kinetics, and the blood drug level of its medicine might be lower than minimum effective blood drug concentration and hold time short shortcoming in treatment concentration.For reaching therapeutic purposes and reducing side effect and often take repeatedly medicining mode, the compliance that makes the patient take medicine like this descends.Slow releasing preparation has overcome the deficiency of conventional formulation just, and steady, persistent blood drug level is provided.
Compound Salviae Miltiorrhizae microsphere of the present invention has adopted the design principle of Western medicine slow releasing preparation to obtain achievement at aspects such as adjuvant selection, quality evaluations, for the research of Chinese medicine slow releasing preparation is used for reference.
Below beneficial effect by extracorporeal releasing test explanation compound Salviae Miltiorrhizae microsphere
Laboratory sample: according to the microsphere of the embodiment of the invention 1,2,3 described method preparations.
Experiment reagent: the buffer solution (4.0,5.5) of certain pH value.
Experimental apparatus: constant temperature oscillator, centrifuge.
Experiment condition: temperature: 37 ± 10 ℃; Rotating speed: 30rp/ minute.
Experimental technique: precision takes by weighing the about 10mg of laboratory sample, and to place volume be the tool lid plastic centrifuge tube of 15ml, adds 5ml release medium (PH=4.0 and 5.5 phosphate buffer solutions) and place constant temperature oscillator, keeps certain temperature and rotating speed to take a sample on time.
Sampling method: centrifugal 50min under the 3600 commentaries on classics conditions, essence is got 3ml solution, adds the release medium of 3ml again, takes out liquid and detects with HPLC.Concrete detection index is a danshensu, detects wavelength: 281nm.
Sampling time point (my god): 0,1,2,4,6,8,10,12,14,16,18,20.
Result of the test: the external release test of huperzine A control-release microsphere is table 1 as a result.
Danshensu release in vitro result in table 1, the compound Salviae Miltiorrhizae control-release microsphere
| Sample | The PH value | Value mode | Discharge percent (%) | |||||||||||
| 0 | 1 | 2 | 4 | 6 | 8 | 10 | 12 | 14 | 16 | 18 | 20 | |||
| Embodiment 1 | 4.0 | The same day | 0 | 26.6 | 4.0 | 0 | 1.5 | 1.15 | 14.0 | 11.95 | 3.0 | 0 | 6.5 | |
| Accumulation | 0 | 26.6 | 30.6 | 30.6 | 33.6 | 35.9 | 63.9 | 87.8 | 93.8 | 93.8 | 106.8 | 106.8 | ||
| 5.5 | The same day | 0 | 28.0 | 2.0 | 2.0 | 1.5 | 1.7 | 29.5 | 16.4 | 1.0 | 0 | 0.5 | ||
| Accumulation | 0 | 28.0 | 30.0 | 30.0 | 33 | 36.4 | 95.4 | 128.2 | 130.2 | 130.2 | 131.2 | 131.2 | ||
| Embodiment 2 | 4.0 | The same day | 0 | 28.3 | 0.3 | 0.3 | 1.1 | 2.1 | 9.0 | 12.35 | 4.8 | 2.8 | 0.85 | 0.5 |
| Accumulation | 0 | 28.3 | 28.6 | 28.6 | 32.7 | 36.9 | 54.9 | 79.6 | 89.2 | 94.8 | 96.5 | 97.5 | ||
| 5.5 | The same day | 0 | 18.1 | 0.9 | 0.9 | 0.05 | 2.65 | 8.6 | 10.5 | 12.7 | 2.05 | 1.2 | 0.6 | |
| Accumulation | 0 | 18.1 | 19.0 | 19.0 | 26.1 | 31.4 | 48.6 | 69.6 | 95.0 | 99.1 | 101.5 | 102.7 | ||
| Embodiment 3 | 4.0 | The same day | 0 | 33.8 | 2.1 | 2.1 | 2.5 | 3.0 | 5.95 | 11.65 | 5.05 | 1.2 | 0.45 | 0.35 |
| Accumulation | 0 | 33.8 | 35.9 | 35.9 | 43.5 | 49.5 | 61.4 | 84.7 | 94.8 | 97.2 | 98.1 | 98.8 | ||
| 5.5 | The same day | 0 | 31.7 | 1.7 | 1.7 | 1.3 | 2.35 | 17.65 | 4.2 | 5.75 | 1.15 | 0.55 | 0.2 | |
| Accumulation | 0 | 31.7 | 33.4 | 33.4 | 39.9 | 44.6 | 79.9 | 88.3 | 99.8 | 102.1 | 103.2 | 103.6 |
The specific embodiment
The present invention is further illustrated below in conjunction with embodiment, and following this embodiment only is used to the present invention is described and to the present invention without limits.
Embodiment 1
Take off and state medical material: Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g;
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: above-mentioned 100mg medicinal substances extract, 200mg polylactide-co-glycolide are dissolved in the 3ml dichloromethane, with syringe under high degree of agitation with it to being equipped with in the three-necked bottle of 10%PVA that 300ml includes the 3.5Ghlb=14 emulsifying agent, after fully emulsified 1 hour, under the pressure of 30 ℃ of 0.03MPa, solvent flashing 1.5 hours, centrifugalize, wash reactant three times with distillation, in 30 ℃ of vacuum drying ovens, dry, sterilized 48 hours at 30 ℃ with oxirane, guarantee residual ethylene oxide content below 5ppm, fill.
Embodiment 2
Take off and state medical material: Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: above-mentioned 100mg medicinal substances extract, 200mg polylactide-co-glycolide are dissolved in the 3ml dichloromethane, with syringe under high degree of agitation with it to being equipped with in the three-necked bottle of 10%PVA that 300ml includes the 3.5Ghlb=14 emulsifying agent, after fully emulsified 1 hour, under the pressure of 30 ℃ of 0.03MPa, solvent flashing 1.5 hours, centrifugalize, wash reactant three times with distillation, in 30 ℃ of vacuum drying ovens, dry, sterilized 48 hours at 30 ℃ with oxirane, guarantee residual ethylene oxide content below 5ppm, fill.
Embodiment 3
The material of getting it filled: Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g;
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: take by weighing the above-mentioned Radix Salviae Miltiorrhizae that obtains, pseudo-ginseng extract 100mg, polylactide-co-glycolide (lactide: Acetic acid, hydroxy-, bimol. cyclic ester=50: 50), 2.0g in small beaker, the 31.5ml that adds methylene chloride, electromagnetic agitation is used filtering with microporous membrane to fully dissolving, adopt the spray drying method for preparation microsphere, record particle diameter 5～80gm, sterilization, packing.
Embodiment 4
Take off and state medical material: Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g;
The extraction of red rooted salvia: get above-mentioned Radix Salviae Miltiorrhizae 41.06g, 20 mesh sieves are pulverized, extracting in water 2 times, the water logging bubble that adds for the first time 9～10 times of amounts, heating extraction 1.5 hours adds 5～7 times of water gagings, heating extraction 1 hour for the second time, merge extractive liquid,, suitably concentrate, add 95% ethanol, make to contain alcohol amount arrival 60%, concentrate and reclaim ethanol, get Radix Salviae Miltiorrhizae extract.
The extraction of pseudo-ginseng: get the 8.03g Radix Notoginseng, add 10 times of amount ethanol extractions of 20% 3 times, reflux 8 hours, merge extractive liquid, concentrates and reclaims ethanol, Radix Notoginseng extract.
The preparation of microsphere: take by weighing and get above-mentioned Radix Salviae Miltiorrhizae extract and the common 100mg (ratio is 1: 1) of Radix Notoginseng extract, polylactide-co-glycolide (lactide: Acetic acid, hydroxy-, bimol. cyclic ester=60: 40), 4.0g in small beaker, the 41ml that adds methylene chloride, electromagnetic agitation adopts the spray drying method for preparation microsphere to fully dissolving, record particle diameter 1～50 μ m, mean diameter 13.26 μ m, sterilization, packing.
Embodiment 5
Take off and state medical material: Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g;
The extraction of red rooted salvia: get above-mentioned Radix Salviae Miltiorrhizae 41.06g, 20 mesh sieves are pulverized, extracting in water 2 times, the water logging bubble that adds for the first time 9～10 times of amounts, heating extraction 1.5 hours adds 5～7 times of water gagings, heating extraction 1 hour for the second time, merge extractive liquid,, suitably concentrate, add 95% ethanol, make to contain alcohol amount arrival 60%, concentrate and reclaim ethanol, get Radix Salviae Miltiorrhizae extract.
The extraction of pseudo-ginseng: get the 8.03g Radix Notoginseng, add 10 times of amount ethanol extractions of 20% 3 times, reflux 8 hours, merge extractive liquid, concentrates and reclaims ethanol, Radix Notoginseng extract.
The preparation of microsphere: with medicinal substances extract 100mg, (lactide: Acetic acid, hydroxy-, bimol. cyclic ester=50: 50) 1.0g places small beaker to polylactide-co-glycolide altogether, adds glacial acetic acid 22ml, electromagnetic agitation adopts the spray drying method for preparation microsphere to fully dissolving, records particle diameter 1～100 μ m, sterilization, packing.
Embodiment 6
Take off and state medical material: Radix Salviae Miltiorrhizae 59.36g Radix Notoginseng 6.38g Borneolum Syntheticum 0.34g
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: with the polylactide-co-glycolide of medicinal substances extract 500mg and 1000mg (lactide: Acetic acid, hydroxy-, bimol. cyclic ester=50: 50) be dissolved in 10ml dichloromethane and be cooled to 15 ℃, include 0.01mol/L with 400ml in addition.The aqueous solution of Tris and 0.01% polyvinyl alcohol (pHt=8.0) is as continuous water, slowly be injected in continuous phase by tubule decentralized photo, at 15 degrees centigrade with emulsator emulsifying 15 minutes, add 1600ml then, 15 ℃ distilled water is used magnetic stirrer 20 minutes, stirs 15 minutes under the evacuation state again, sieve, lyophilized promptly gets 1～10 micron microsphere.
Embodiment 7
Take off and state medical material: Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: take by weighing medicinal substances extract 100mg, polylactic acid-polyglycolic acid, 4.0g are in small beaker, and 41ml adds methylene chloride, electromagnetic agitation adopts the spray drying method for preparation microsphere to fully dissolving, records particle diameter 1～50 μ m, mean diameter 13.261 μ m, sterilization, packing.
Embodiment 8
Take off and state medical material: Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g
The extraction of Salvia miltiorrhiza and Panax notoginseng medical material: the Radix Salviae Miltiorrhizae of the coarse pulverization of learning from else's experience, pseudo-ginseng add 5 times of water gagings to extraction pot, decoct 2 hours, filter, and filtering residue carries out the second time and extracts, and adds 4 times of water gagings, decocts 1 hour, filters, and filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol is condensed into extractum.
The preparation of microsphere: 100mg drug extract, poly butyric ester-hydroxyl valerate 200mg are dissolved in the 3ml dichloromethane, under high degree of agitation, it are included 10% of 3.5Ghlb=14 emulsifying agent to 300ml is housed with syringe.In the three-necked bottle of PVA, after fully emulsified 1 hour, under the pressure of 30 ℃ of 0.03MPa, solvent flashing 1.5 hours, centrifugalize is washed reactant three times with distillation, in 30 ℃ of vacuum drying ovens, dry, 30 ℃ of sterilizations 48 hours, guarantee residual ethylene oxide content below 5ppm, fill with oxirane.
Claims (13)
1. compound red sage root extended release microsphere, comprise 0.2～50% be that 50～99.8% molecular weight ranges of active component and microsphere weight is 5 by the extract of Radix Salviae Miltiorrhizae, pseudo-ginseng and Borneolum Syntheticum, 000～1, the biodegradable medicinal high polymer adjuvant between 000,000 is formed.
2. the described microsphere of claim 1, wherein said medicinal high polymer adjuvant are selected from polylactide-co-glycolide, polylactic acid, polyglycolic acid, poly--the 3-butyric ester, polylactic acid-polyglycolic acid, polylactic acid. glycolic, poly-adjacent ester, polylactone, polyanhydride, poly butyric ester-hydroxyl pentanoate copolymer, polyglycolic acid, polypropylene glucosan, hydroxyacetic acid, polylactic acid-polyglycol, polyglycolic acid. and Polyethylene Glycol a kind of or two or more mixing wherein wherein.
3. the described microsphere of claim 1, wherein said medicinal high polymer adjuvant is selected from polylactide-co-glycolide, polylactic acid, polylactic acid. wherein a kind of of polyglycolic acid, polylactic acid-glycollic acid, poly butyric ester-hydroxyl pentanoate copolymer or two or more mixing wherein.
4. the described microsphere of claim 1, wherein medicinal high polymer adjuvant is a polylactide-co-glycolide.
5. the described microsphere of claim 1, its molecular weight of wherein said polylactide-co-glycolide is between 12000～15000 dalton.
6. the described microsphere of claim 1, wherein in the polylactide-co-glycolide lactide and Acetic acid, hydroxy-, bimol. cyclic ester polymerization ratio between 40: 60～60: 40.
7. the described microsphere of claim 1, the weight percentage of active component Radix Salviae Miltiorrhizae wherein, Radix Notoginseng and Borneolum Syntheticum crude drug is a Radix Salviae Miltiorrhizae 48%～97%, Radix Notoginseng 2%～50%, Borneolum Syntheticum 0.2%～3%.
8. the described microsphere of claim 1, the weight percentage of active component Radix Salviae Miltiorrhizae wherein, Radix Notoginseng and Borneolum Syntheticum crude drug is a Radix Salviae Miltiorrhizae 63.0%～94%, Radix Notoginseng 4.0%～35.0%, Borneolum Syntheticum 0.5%～2.0%.
9. the described microsphere of claim 1, the weight percentage of active component Radix Salviae Miltiorrhizae wherein, Radix Notoginseng and Borneolum Syntheticum crude drug is a Radix Salviae Miltiorrhizae 75.2%～90%, Radix Notoginseng 9%～23.5%, Borneolum Syntheticum 0.5%～1.3%.
10. the described microsphere of claim 1, the weight percentage of active component Radix Salviae Miltiorrhizae wherein, Radix Notoginseng and Borneolum Syntheticum crude drug is a Radix Salviae Miltiorrhizae 82.87%, Radix Notoginseng 16.21%, Borneolum Syntheticum 0.92%.
11. the preparation method of the described microsphere of claim 1, it is to adopt the emulsifying dispersion method to make, it is characterized in that using dichloromethane, chloroform, ethyl acetate, dioxane, ether, acetone, oxolane, glacial acetic acid and the mixed acid be made up of them are medicinal substances extract and the dissolving of biodegradable pharmaceutic adjuvant, wherein the bulking value percent of pharmaceutic adjuvant in organic solvent is 1～30%, the emulsifying agent that organic facies adopts is the nonionic emulsifier of HLB=4.5～6.0, uses polyvinyl alcohol, polyvinyl pyrrolidone, consumption is 0.01～12% of an organic facies; Sodium polymethacrylate, sodium polyacrylate, sodium carboxymethyl cellulose solution in addition, prepare continuous water, wherein they are 0.01～10.0 in the percetage by weight of aqueous phase, and the emulsifying agent of aqueous phase is the nonionic emulsifier of HLB=14.0～15.5, and consumption is 0.01～12% of a water; Decentralized photo slowly is injected in the continuous phase by tubule, and emulsifying is sieved then, is drying to obtain.
12. the preparation method of the described microsphere of claim 1, it is to adopt solvent evaporation method to make, the mixed acid that it is characterized in that forming with dichloromethane, chloroform, ethyl acetate, dioxane, ether, acetone, oxolane, glacial acetic acid and by them is medicinal substances extract and the dissolving of biodegradable pharmaceutic adjuvant, wherein the bulking value percent of pharmaceutic adjuvant in organic solvent is 1～30%, the emulsifying agent that organic facies adopts is the nonionic emulsifier of HLB=4.5～6.0, and consumption is 0.01～12% of an organic facies; Use polyvinyl alcohol, polyvinyl pyrrolidone, sodium polymethacrylate, sodium polyacrylate, sodium carboxymethyl cellulose solution in addition, prepare continuous water, wherein they are 0.01～10.0 in the percetage by weight of aqueous phase, the emulsifying agent of aqueous phase is the nonionic emulsifier of HLB=14.0～15.5, and consumption is 0.01～12% of a water; Decentralized photo slowly is injected in the continuous phase by tubule, fully emulsified, the solvent flashing that reduces pressure then, centrifugalize is drying to obtain.
13. the preparation method of the described microsphere of claim 1, it is to adopt spray drying method to make, the molecular weight that it is characterized in that mixed-acid dissolution 0.2～50% medicinal substances extract formed with dichloromethane, chloroform, ethyl acetate, dioxane, ether, acetone, oxolane, glacial acetic acid and by them and derivant and 50～99.8% is at 5000～1000000 daltonian biodegradable medical high-molecular additives, after stirring fully dissolving, filter, adopt spray drying method to make microsphere.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410093890 CN1785253B (en) | 2004-12-10 | 2004-12-10 | Micro-balls of compound red-rooted salvia injection, and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410093890 CN1785253B (en) | 2004-12-10 | 2004-12-10 | Micro-balls of compound red-rooted salvia injection, and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1785253A true CN1785253A (en) | 2006-06-14 |
| CN1785253B CN1785253B (en) | 2010-04-28 |
Family
ID=36782922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410093890 Expired - Fee Related CN1785253B (en) | 2004-12-10 | 2004-12-10 | Micro-balls of compound red-rooted salvia injection, and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1785253B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070898A (en) * | 2013-01-29 | 2013-05-01 | 广东药学院 | Salvia miltiorrhiza and panax notoginseng compound nano suspension |
| CN105586304A (en) * | 2014-11-18 | 2016-05-18 | 北京化工大学 | Recombinant strain for producing glycolate based polymers and application of recombinant strain |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1161140C (en) * | 2001-11-09 | 2004-08-11 | 天津天士力制药股份有限公司 | Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use |
| CN1349818A (en) * | 2001-10-24 | 2002-05-22 | 沈阳药科大学 | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process |
| CN1166360C (en) * | 2002-11-07 | 2004-09-15 | 上海医药工业研究院 | Long acting injection microsphere combination of naltrexone, its preparation method and application |
-
2004
- 2004-12-10 CN CN 200410093890 patent/CN1785253B/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103070898A (en) * | 2013-01-29 | 2013-05-01 | 广东药学院 | Salvia miltiorrhiza and panax notoginseng compound nano suspension |
| CN103070898B (en) * | 2013-01-29 | 2014-04-30 | 广东药学院 | Salvia miltiorrhiza and panax notoginseng compound nano suspension |
| CN105586304A (en) * | 2014-11-18 | 2016-05-18 | 北京化工大学 | Recombinant strain for producing glycolate based polymers and application of recombinant strain |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1785253B (en) | 2010-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1706397A (en) | Composition of paeoniflorin and peony lactone glycoside with function of increasing leukocyte | |
| CN1903213A (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN1872155A (en) | Microspheres in use for injection of astragalus root and red sage root, and preparation method | |
| CN1785253B (en) | Micro-balls of compound red-rooted salvia injection, and its preparation method | |
| CN1698717A (en) | Chinese medicinal compound fat emulsion injection and its preparation method | |
| CN1698803A (en) | Compound notoginseng injection and its preparation process | |
| CN1872179B (en) | Microspheres in use for injection of Chinese traditional medicine of containing astragalus root, and preparation method | |
| CN1248698C (en) | Drug for treating coronary heart disease or coronary disease and cardiac insufficiency, and its preparation method | |
| CN1522746A (en) | Gadol pharmaceutical preparation, method for making same and uses | |
| CN1817356A (en) | Production of vermilion injection for treating cardiovascular disease | |
| CN1872156A (en) | Microspheres in use for injection of anginin, and prepartion method | |
| CN101073598A (en) | Medicinal composition for treating cardiovascular and cerebrovascular disease and its preparation | |
| CN1872101A (en) | Distillage of Ardisia chinensis Benth of possessing function of antivirus, distilling method and application | |
| CN1291733C (en) | Chinese medicine composition for treating cardiac and cerebral vascular diseases and its prepn process | |
| CN1872251A (en) | Microspheres in use for injection of Chinese traditional medicine for treating senile dementia, and preparation method | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1872212A (en) | Microspheres in use for injection of Chinese traditional medicine of containing angelica, and preparation method | |
| CN1290520C (en) | Method for preparing hepatitis treating medicine and the product produced thereby | |
| CN1857370A (en) | Notoginseng hemostatic and its preparing method | |
| CN1364486A (en) | Nano ten ingredient restoration medicine and its preparing method | |
| CN1872158A (en) | Microspheres in use for injection of total phenolic acids of red sage root, and preparation method | |
| CN1706409A (en) | Prepn process of garden burnet prepn | |
| CN1883609B (en) | Chinese medicinal microsphere containing peach kernel for injection and method for preparing same | |
| CN1785252A (en) | Delayed-release compounding tablets contg. red-rooted salvia gel skeleton, and its prepn. method | |
| CN1386526A (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARM. CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100428 Termination date: 20191210 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |